Eisai's Halaven Faces Another Reimbursement Roadblock In Germany
Executive Summary
Eisai's cancer drug Halaven has suffered another reimbursement setback in Europe, with Germany's health technology appraisal body IQWiG slapping its "no additional benefit" rating on the product for use in patients with advanced liposarcoma.